-
Posted by
Two Blokes Jul 18 -
Filed in
Stock
-
2 views
Shares of Sarepta Therapeutics plunged more than 30% on Friday after Food and Drug Administration Commissioner Marty Makary said the agency is considering whether the company's gene therapy should stay on the market. Sarepta has reported three patient deaths related to its gene therapies.
